Our objectives are to investigate basic aspects of brain tumors (especially gliomas) in etiological, immunological, tumor biological, and experimental chemotherapeutic areas. In etiological studies, we will seek the association of retroviruses and human papovaviruses with spontaneous human or animal gliomas, establish the transplacental neuro-oncogenicity of acrylonitrile, study genetic susceptibility of mice to neuro-oncogenetic viruses and chemical carcinogens, and use banding and nonbanding cytogenetic techniques to guide etiological studies of animal and human gliomas. In immunological studies, we will purify and characterize antigens associated with spontaneous human and mouse gliomas and determine if quantitation of these antigens can be used to monitor tumor size and as an adjunct in diagnosis. In tumor biological studies, we will establish whether or not the phenotypic heterogeneity of neoplastic cells in human gliomas with respect to morphological, biochemical, and immunological differentiation extends to chemotherapeutic sensitivity as tested in athymic mice and whether endothelial cells of human and experimental gliomas are neoplastic. We will use a human glioma animal model to test intracarotid chemotherapy and radioimmunotherapy with radioiodinated monoclonal antibodies against human gliomas in rats. (TA)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA011898-15
Application #
3163570
Study Section
Pathology A Study Section (PTHA)
Project Start
1976-12-01
Project End
1988-03-31
Budget Start
1985-04-01
Budget End
1986-03-31
Support Year
15
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Koroukian, Siran M; Bakaki, Paul M; Golchin, Negar et al. (2012) Mental illness and use of screening mammography among Medicaid beneficiaries. Am J Prev Med 42:606-9
Reardon, David A; Vredenburgh, James J; Desjardins, Annick et al. (2012) Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol 108:499-506
Reardon, David A; Vredenburgh, James J; Desjardins, Annick et al. (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101:57-66
Reardon, David A; Vredenburgh, James J; Coan, April et al. (2011) Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 105:621-7
Bettegowda, Chetan; Agrawal, Nishant; Jiao, Yuchen et al. (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453-5
Reardon, David A; Desjardins, Annick; Vredenburgh, James J et al. (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219-30
Kato, Yukinari; Jin, Genglin; Kuan, Chien-Tsun et al. (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547-51
Reardon, David A; Wen, Patrick Y; Desjardins, Annick et al. (2008) Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 8:541-53
Zalutsky, Michael R; Reardon, David A; Akabani, Gamal et al. (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49:30-8
Reardon, David A; Nabors, L Burt; Stupp, Roger et al. (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17:1225-35

Showing the most recent 10 out of 211 publications